HRGN (Harvard Apparatus Regenerative Technology) Total Liabilities: $1.71 Mil (As of Mar. 2026)


HRGN Harvard Apparatus Regenerative Technology Inc HRGN
27 GF Score
Price $1.05
GF Value $5.34
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Harvard Apparatus Regenerative Technology Total Liabilities?

Harvard Apparatus Regenerative Technology HRGN 27 Total Liabilities is $1.71 Mil as of Mar. 2026. GuruFocus rates HRGN with a GF Score™ of 27/100 and a GF Value™ of $5.34 (Possible Value Trap). The stock has 2 warning signs investors should review.

Harvard Apparatus Regenerative Technology's Total Liabilities for the quarter that ended in Mar. 2026 was $1.71 Mil.

Harvard Apparatus Regenerative Technology's quarterly Total Liabilities increased from Sep. 2025 ($0.99 Mil) to Dec. 2025 ($1.62 Mil) and increased from Dec. 2025 ($1.62 Mil) to Mar. 2026 ($1.71 Mil).

Harvard Apparatus Regenerative Technology's annual Total Liabilities increased from Dec. 2023 ($0.97 Mil) to Dec. 2024 ($1.22 Mil) and increased from Dec. 2024 ($1.22 Mil) to Dec. 2025 ($1.62 Mil).

Harvard Apparatus Regenerative Technology Total Liabilities Historical Data

* Premium members only.

The historical data trend for Harvard Apparatus Regenerative Technology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Apparatus Regenerative Technology Total Liabilities Chart

Harvard Apparatus Regenerative Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.90 1.41 0.97 1.22 1.62

Harvard Apparatus Regenerative Technology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 1.38 0.99 1.62 1.71
HRGN
27GF Score
Harvard Apparatus Regenerative Technology Inc HRGN
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Apparatus Regenerative Technology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Harvard Apparatus Regenerative Technology's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.534+(0.086+8.3266726846887E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.62

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=2.677-1.057
=1.62

Harvard Apparatus Regenerative Technology's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.651+(0.055+-6.2450045135165E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.71

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=1.798-0.092
=1.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $1.71 Mil mean?
Harvard Apparatus Regenerative Technology (HRGN) has a Total Liabilities of $1.71 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Harvard Apparatus Regenerative Technology and its competitors.
Is Harvard Apparatus Regenerative Technology's Total Liabilities too high?
Harvard Apparatus Regenerative Technology's current Total Liabilities is $1.71 Mil. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's Total Liabilities compare to DTEAF and STCB?
Harvard Apparatus Regenerative Technology's Total Liabilities of $1.71 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Consumer Packaged Goods company?
A good Total Liabilities depends on the Consumer Packaged Goods industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Harvard Apparatus Regenerative Technology and its competitors. Harvard Apparatus Regenerative Technology's current Total Liabilities is $1.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology (HRGN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.34, compared to a current price of $1.05 — trading 80.3% below its estimated fair value. The current Total Liabilities is $1.71 Mil. Harvard Apparatus Regenerative Technology's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current Total Liabilities is $1.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Apparatus Regenerative Technology (HRGN) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology stock appears to be undervalued. The current stock price of $1.05 is trading 80.3% below its estimated GF Value™ of $5.34. GuruFocus considers Harvard Apparatus Regenerative Technology to be Possible Value Trap.

Key valuation signals for HRGN:

  • Total Liabilities: $1.71 Mil
  • GF Value™: $5.34 vs. price of $1.05 (80.3% below fair value)
  • GF Score™: 27/100 with 2 warning signs

No single metric tells the full story. See the HRGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harvard Apparatus Regenerative Technology Business Description

Address 84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
27GF Score

Get the complete analysis for HRGN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.05
Price
$5.34
GF Value